Table 1.
Indication for ceftazidime–avibactam
| Total (N = 516) | |
|---|---|
| Indication, n (%) | |
| HAP/VAP | 114 (22.1) |
| cUTI | 103 (20.0) |
| BSI | 97 (18.8) |
| cIAI | 90 (17.4) |
| Other | 112 (21.7) |
| Febrile neutropenia | 24 (4.7) |
| SSI | 15 (2.9) |
| CLABSI | 15 (2.9) |
| Osteomyelitis | 7 (1.4) |
| Others | 51 (9.9) |
| Diagnosis of COVID-19, n (%) | |
| Yes | 63 (12.2) |
| No | 247 (47.9) |
| Patients enrolled before COVID-19 pandemic | 206 (39.9) |
BSI bloodstream infection, cIAI complicated intra-abdominal infections, CLABSI central-line associated bloodstream infections, COVID-19 coronavirus disease 2019, cUTI complicated urinary tract infections, HAP hospital-acquired pneumonia, SSI surgical site infections, VAP ventilator-acquired pneumonia